Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1126.01%
operating margin TTM
-1194.16%
revenue TTM
41.22 Million
revenue per share TTM
0.59$
valuation ratios | |
|---|---|
| pe ratio | -11.26 |
| peg ratio | -2.38 |
| price to book ratio | 4.03 |
| price to sales ratio | 136.85 |
| enterprise value multiple | -12.11 |
| price fair value | 4.03 |
profitability ratios | |
|---|---|
| gross profit margin | 90.99% |
| operating profit margin | -1194.16% |
| pretax profit margin | -1126.01% |
| net profit margin | -1126.01% |
| return on assets | -29.99% |
| return on equity | -40.45% |
| return on capital employed | -36.21% |
liquidity ratio | |
|---|---|
| current ratio | 7.54 |
| quick ratio | 7.40 |
| cash ratio | 1.88 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 2,713.74 |
| operating cycle | 2,957.91 |
| days of payables outstanding | 5,110.94 |
| cash conversion cycle | -2,153.04 |
| receivables turnover | 1.49 |
| payables turnover | 0.07 |
| inventory turnover | 0.13 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -34.30 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.24 |
| cash per share | 15.02 |
| operating cash flow per share | -4.23 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -34.30 |
| short term coverage ratios | -34.30 |
| capital expenditure coverage ratio | -362.95 |
Frequently Asked Questions
When was the last time Mirati Therapeutics, Inc. (NASDAQ:MRTX) reported earnings?
Mirati Therapeutics, Inc. (MRTX) published its most recent earnings results on 06-11-2023.
What is Mirati Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Mirati Therapeutics, Inc. (NASDAQ:MRTX)'s trailing twelve months ROE is -40.45%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Mirati Therapeutics, Inc. (MRTX) currently has a ROA of -29.99%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did MRTX's net profit margin stand at?
MRTX reported a profit margin of -1126.01% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is MRTX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.54 in the most recent quarter. The quick ratio stood at 7.40, with a Debt/Eq ratio of 0.01.